Paresh Dandona
YOU?
Author Swipe
View article: 12608 Preserving Lean Body Mass During Weight Loss In Elderly Obese Patients With Glp-1 Receptor Agonist Treatment
12608 Preserving Lean Body Mass During Weight Loss In Elderly Obese Patients With Glp-1 Receptor Agonist Treatment Open
Disclosure: H. Ghanim: None. A. Chaudhuri: None. J. Hejna: None. P. Dandona: None. Preserving Lean Body Mass During Weight Loss in Elderly Obese Patients with GLP-1 Receptor Agonist Treatment Background and Rational: Since aging process is…
View article: 9232 Assessing the Risk of Recurrence in Acute Pancreatitis Among Patients with Type 2 Diabetes Initiating GLP-1 Receptor Agonists Therapy
9232 Assessing the Risk of Recurrence in Acute Pancreatitis Among Patients with Type 2 Diabetes Initiating GLP-1 Receptor Agonists Therapy Open
Disclosure: M. Nassar: None. H. Abosheaishaa: None. P. Dandona: None. H. Ghanim: None. A. Chaudhuri: None. Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are recognized therapeutic agents for patients with type 2 diabete…
View article: 6531 Assessing the Risk of Recurrence in Acute Pancreatitis Among Patients with Type 2 Diabetes Initiating GLP-1 Receptor Agonists Therapy
6531 Assessing the Risk of Recurrence in Acute Pancreatitis Among Patients with Type 2 Diabetes Initiating GLP-1 Receptor Agonists Therapy Open
Disclosure: M. Nassar: None. H. Abosheaishaa: None. P. Dandona: None. H. Ghanim: None. A. Chaudhuri: None. Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are recognized therapeutic agents for patients with type 2 diabete…
View article: Glucagon-like peptide-1 receptor agonists as a possible intervention to delay the onset of type 1 diabetes: A new horizon
Glucagon-like peptide-1 receptor agonists as a possible intervention to delay the onset of type 1 diabetes: A new horizon Open
Type 1 diabetes (T1D) is a chronic autoimmune condition that destroys insulin-producing beta cells in the pancreas, leading to insulin deficiency and hyper-glycemia. The management of T1D primarily focuses on exogenous insulin replacement …
View article: THU457 Variable Presentations Of Hypophosphatasia In Two Patients In The Outpatient Setting
THU457 Variable Presentations Of Hypophosphatasia In Two Patients In The Outpatient Setting Open
Disclosure: A. Elmaaz: None. S. Batool: None. P. Dandona: None. Introduction: Hypophosphatasia is a rare disorder characterized by defective mineralization of bone and teeth which is caused by an autosomal inherited mutation in the tissue …
View article: SAT367 A Rare Case of Ovarian Cellular Fibroma Producing Testosterone
SAT367 A Rare Case of Ovarian Cellular Fibroma Producing Testosterone Open
Disclosure: H.K. Rai: None. P. Dandona: None. Background: Ovarian fibromas are hormonally inactive, benign sex cord-stromal tumors. However, the occurrence of ovarian fibromas in a woman presenting with post-menopausal bleeding, hirsutism,…
View article: Vasoactive mediators of hypertension in obesity
Vasoactive mediators of hypertension in obesity Open
Our data show that obesity, especially morbid obesity, is associated with higher blood pressure levels and increases angiotensin II and endotherlin-1 (ET-1) (vasoconstrictors) and lower levels BNP and cGMP (vasodilators) and that systolic …
View article: Insulin Resistance and Glycated Hemoglobin in Obesity Are Associated With Preference for Sugar-Sweetened Yogurt: A Pilot Study
Insulin Resistance and Glycated Hemoglobin in Obesity Are Associated With Preference for Sugar-Sweetened Yogurt: A Pilot Study Open
Objective Insulin resistance is associated with elevated activation of food reward, which should be associated with an increased reinforcing value of food. Research has also shown that sugar is a macronutrient strongly associated with rewa…
View article: Recognizing the True Value of Testosterone Therapy in Health Care
Recognizing the True Value of Testosterone Therapy in Health Care Open
There has been little recognition within the medical community of the health impact of testosterone (T) deficiency (TD), also known as hypogonadism, and the substantial benefits of testosterone therapy (TTh) on health and quality of life d…
View article: LBSUN213 An Investigation Into The Effects Of Dapagliflozin On Ketogenesis In Type 1 Diabetes
LBSUN213 An Investigation Into The Effects Of Dapagliflozin On Ketogenesis In Type 1 Diabetes Open
Background Treatment with sodium-glucose transporter (SGLT)-2 inhibitors in patients with type 1 diabetes (T1DM) is associated with increased ketogenesis and diabetic ketoacidosis (DKA). The exact relationship between SGLT-2 inhibitors use…
View article: The side effects of immune checkpoint inhibitor therapy on the endocrine system
The side effects of immune checkpoint inhibitor therapy on the endocrine system Open
Immune checkpoint inhibitors (ICIs) are a relatively newer class of drugs approved for the treatment of malignancies such as melanoma, renal, bladder and lung cancer. Immune-related adverse events (IrAEs) involving the endocrine system are…
View article: 4-Phenylbutyric acid improves free fatty acid-induced hepatic insulin resistance in vivo
4-Phenylbutyric acid improves free fatty acid-induced hepatic insulin resistance in vivo Open
Plasma free fatty acids (FFAs) are elevated in obesity and can induce insulin resistance via endoplasmic reticulum (ER) stress. However, it is unknown whether hepatic insulin resistance caused by the elevation of plasma FFAs is alleviated …
View article: The Story of a Radiologically Undetectable, Testosterone Producing Leydig Cell Tumor
The Story of a Radiologically Undetectable, Testosterone Producing Leydig Cell Tumor Open
Introduction: Leydig stromal cell tumors are uncommon ovarian tumors that produce testosterone leading to hyperandrogenism. We present a case of a 63 year old lady with significantly elevated testosterone levels that did not have clear ova…
View article: Effective Initiation and Treatment With Basal Insulin in People With Type 2 Diabetes: Focus on Mitigating Hypoglycemia in Patients at Increased Risk
Effective Initiation and Treatment With Basal Insulin in People With Type 2 Diabetes: Focus on Mitigating Hypoglycemia in Patients at Increased Risk Open
Many people with type 2 diabetes are treated with insulin with the goal of achieving a specific A1C target. In this short video series, an expert panel moderated by John Anderson, MD, discusses approaches to optimizing basal insulin initia…
View article: Effective Initiation and Treatment With Basal Insulin in People With Type 2 Diabetes: Focus on Mitigating Hypoglycemia in Patients at Increased Risk
Effective Initiation and Treatment With Basal Insulin in People With Type 2 Diabetes: Focus on Mitigating Hypoglycemia in Patients at Increased Risk Open
Many people with type 2 diabetes are treated with insulin with the goal of achieving a specific A1C target. In this short video series, an expert panel moderated by John Anderson, MD, discusses approaches to optimizing basal insulin initia…
View article: <scp>Long‐term</scp> efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled <scp>52‐week</scp> outcomes from the <scp>DEPICT</scp> ‐1 and ‐2 studies
<span>Long‐term</span> efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled <span>52‐week</span> outcomes from the <span>DEPICT</span> ‐1 and ‐2 studies Open
Aim To evaluate the efficacy and safety of adjunct dapagliflozin therapy in patients with type 1 diabetes (T1D). Materials and Methods DEPICT‐1 and ‐2 were randomized, double‐blind, parallel‐group, 24‐week studies, with 28‐week extension p…
View article: Testosterone Decreases Erythropoietin Stimulating Agent Use in Men on Hemodialysis
Testosterone Decreases Erythropoietin Stimulating Agent Use in Men on Hemodialysis Open
Objective: Erythropoiesis stimulating agents (ESAs) are required in most of the patients with end-stage renal disease (ESRD) for treatment of anemia. Subnormal testosterone concentrations are very common in men with ESRD. Since testosteron…
View article: Effective Initiation and Treatment With Basal Insulin in People With Type 2 Diabetes: Focus on Mitigating Hypoglycemia in Patients at Increased Risk: Executive Summary
Effective Initiation and Treatment With Basal Insulin in People With Type 2 Diabetes: Focus on Mitigating Hypoglycemia in Patients at Increased Risk: Executive Summary Open
Many people with type 2 diabetes are treated with insulin with the goal of achieving a specific A1C target. The most prominent risk for people on insulin therapy is hypoglycemia. When basal insulin analogs are used appropriately, the risk …
View article: Narcolepsy, depression, and severe flushing in an obese man
Narcolepsy, depression, and severe flushing in an obese man Open
Hypogonadism as a cause of depression, daytime sleepiness, and flushing is often missed in young males. Our case report highlights the importance of screening for hypogonadotropic hypogonadism and its treatment in symptomatic men with seve…
View article: Bariatric Surgery: Remission of Inflammation, Cardiometabolic Benefits, and Common Adverse Effects
Bariatric Surgery: Remission of Inflammation, Cardiometabolic Benefits, and Common Adverse Effects Open
Obesity is associated with increased mortality as a result of several comorbidities which occur in tandem with the obese state. Chronic inflammation is well documented in obesity, and evidence from numerous studies support the notion that …
View article: Benefit/risk profile of dapagliflozin 5 mg in the <scp>DEPICT</scp> ‐1 and ‐2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m <sup>2</sup>
Benefit/risk profile of dapagliflozin 5 mg in the <span>DEPICT</span> ‐1 and ‐2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m <sup>2</sup> Open
Aim The DEPICT‐1 and ‐2 studies (NCT02268214, NCT02460978) evaluated the efficacy and safety of dapagliflozin in individuals with type 1 diabetes who were receiving intensive insulin therapy. The DEPICT‐1 and ‐2 studies (NCT02268214, NCT02…